Barclays Keeps Their Buy Rating on Bruker (BRKR)

In a report released today, Luke Sergott from Barclays maintained a Buy rating on Bruker, with a price target of $55.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Sergott covers the Healthcare sector, focusing on stocks such as Revvity, Mettler-Toledo, and Exact Sciences. According to TipRanks, Sergott has an average return of -0.2% and a 45.58% success rate on recommended stocks.

In addition to Barclays, Bruker also received a Buy from Guggenheim’s Subbu Nambi in a report issued on January 26. However, on the same day, TipRanks – DeepSeek reiterated a Hold rating on Bruker (NASDAQ: BRKR).

Based on Bruker’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $860.5 million and a GAAP net loss of $59.6 million. In comparison, last year the company earned a revenue of $864.4 million and had a net profit of $40.9 million

Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BRKR in relation to earlier this year. Most recently, in December 2025, Richard Packer, a Director at BRKR sold 5,028.00 shares for a total of $243,204.36.